Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Feb 26;21(3):22.
doi: 10.1007/s11912-019-0771-9.

Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development

Jessica Gillen  1 , Debra Richardson  1 , Kathleen Moore  2
Affiliations
Review

Angiopoietin-1 and Angiopoietin-2 Inhibitors: Clinical Development

Jessica Gillen et al. Curr Oncol Rep. .

Abstract

Purpose of review: The purpose of this review is to discuss the current understanding of the Tie2-angiopoietin system and its role in tumor growth and metastasis. This review also focuses on preclinical and clinical data published to date that have evaluated Tie2-angiopoietin inhibition.

Recent findings: Tie2 inhibition has shown significant promise in preclinical models, notable for decreased tumor burden and fewer sites of metastatic disease across various malignancies. However, data from human clinical trials have shown more mixed results. Trebananib, rebastanib, and MEDI3617 are the three Tie2-angiopoietin inhibitors that have been most widely evaluated in phase I and II trials. Further investigation into these therapies is ongoing. The Tie2-angiopoietin pathway continues to show promise in preclinical and some clinical trials, including studies on recurrent or metastatic breast and renal cell carcinomas. Further evaluation of these therapies, however, is warranted to better understand their optimal clinical utility.

Keywords: Angiogenesis; Angiopoietin inhibition; Anti-angiogenic therapy; Tie2 inhibition.

PubMed Disclaimer

References

    1. Genes Dev. 1999 May 1;13(9):1055-66 - PubMed
    1. Semin Oncol. 2002 Dec;29(6 Suppl 16):15-8 - PubMed
    1. Chest. 2007 Jul;132(1):200-6 - PubMed
    1. Nat Rev Cancer. 2008 Aug;8(8):592-603 - PubMed
    1. Nat Rev Mol Cell Biol. 2009 Mar;10(3):165-77 - PubMed

MeSH terms

LinkOut - more resources